Etoposide

Catalog No.S1225 Synonyms: VP-16, VP-16213

Etoposide Chemical Structure

Molecular Weight(MW): 588.56

Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 280 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  • ABT-199 synergizes strongly with lymphoma chemotherapy agents that affect MCL1 levels. Viability and CI vs Fa after 24-h exposure to etoposide alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM.

    Leukemia, 2015, 29: 1702–1712. Etoposide purchased from Selleck.

    Dox promotes formation of DNA DSBs in primary neurons. (A) Cortical neurons at 28–32 DIV were treated with a vehicle or with Dox (0.1 μ M) or with DNA damaging drug etoposide (5 μ M) overnight, fixed, and stained for a marker of DSBs phosphorylated histone H2A variant X, γ H2A.X (green), MAP2c (red), and with the nuclear Hoechst dye (blue), and imaged. The neuronal nucleus is enlarged on the Dox panel to illustrate the γ H2A.X puncta. Note the green nuclear staining in cells treated with Dox and etoposide. Also note the reduced dendritic arborization in neurons treated with Dox and etoposide. Scale bar is 20 μm.

    Sci Rep, 2016, 6:25705.. Etoposide purchased from Selleck.

  • Viability of U87 cells(C) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs etoposide (ETO) and Bliss interaction index (D) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 1.5 μM ETO (C) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-19.. Etoposide purchased from Selleck.

    Cellular biomarker responses in HT29 cells exposed to various cytotoxic chemotherapeutic agents in combination with the Chk1 inhibitor V158411. HT29 cells were exposed to the combination GI80 of gemcitabine (0.2 uM), camptothecin (0.44 uM), cisplatin (68 uM), oxaliplatin (131 uM), doxorubicin (1.2 uM) or etoposide (59 uM) for 18 hours followed by DMSO (-) or 400 nM V158411 (+) for a further 24 hours. Protein expression was characterized by immunoblotting.

    BMC Cancer 2014 14, 483. Etoposide purchased from Selleck.

  • (c) and (d) Effects of fractions C4 and C5 on topoisomerase II activity. Topoisomerase II activity was measured by plasmid DNA cleavage assay. DNA bands were visualized using UV light and the intensity of linear DNA band in each lane was measured using imageJ software. Lane 1: plasmid PBR322DNA. Lane 2: control, topoisomerase II + plasmid PBR322DNA. Lanes 3, 4, and 5: 40, 20, and 10 μg/mL fraction C4 + plasmid PBR322DNA, respectively. Lanes 6, 7, and 8: 40, 20, and 10 μg/mL fraction C5 + plasmid PBR322DNA, respectively. Lane 9: 100 μM etoposide + plasmid PBR322DNA. The data in different groups were expressed as the mean ± SD from 3 experiments. Statistical difference between groups was assessed by t-test using SPSS 20.0. ∗∗P < 0.01 versus the control group.

    Evid Based Complement Alternat Med, 2017, 2017:1456786. Etoposide purchased from Selleck.

    Effects of etoposide on the radiosensitivities of cholangiocarcinoma cell lines. The cell survival curves of (A) KKU-M055 and (B) KKU-M214 cells were obtained from clonogenic survival assays. The cells were treated with X-ray irradiation or etoposide (0.025 or 0.05 µg/ml) alone or pretreated with etoposide for 24 h prior to X-ray irradiation. Survival fractions were determined at day 10 following X-ray irradiation. The dose-response curves depict the mean ± standard deviation of survival fractions of three independent experiments. IR, irradiation.

    Oncol Lett, 2018, 15(3):3895-3903. Etoposide purchased from Selleck.

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Biological Activity

Description Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.
Targets
Topo II [2]
(Cell-free assay)
In vitro

Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, which induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [1] Etoposide inhibits the growth of murine angiosarcoma cell line (ISOS-1) in a 5 days-period with IC50 of 0.25 μg/mL. Cell growth of normal murine microvascular endothelial cells (mECs) is less sensitive to Etoposide with IC50 of 10 μg/mL). [2] Etoposide treated for 6 hr inhibits colonies of tetraploid variant of the human leukemic lymphoblast line CCRF-CEM with IC50 of 0.6 μM. [3] Etoposide treated for 2 hr inhibits growth of human pancreatic cancer cell line Y1, Y3, Y5, Y19, YM. YS, and YT with IC50s of 300 μg/mL, 300 μg/mL, 300 μg/mL, 91 μg/mL, 0.68 μg/mL, 300 μg/mL, 300 μg/mL, and 260 μg/mL, respectively. [4] Etoposide exposed for 1 hr inhibits growth of human glioma cell lines CL5, G142, G152, G111, and G5 with IC50 of 8, 9, 9.8, 10, and 15.8 μg/mL respectively for 12 days. Under same condition, the IC90 value is attained in cell lines CL5, G152, G142, and G111 at 26, 27, 32, and 33 μg/mL. Etoposide inhibition of topoisomerase II is homogeneous for each cell. The average inhibition rates are 15%, 21.8%, 31.8%, 41.5%, and 49.5% for 1, 2, 4, 8, and 16 μg Etoposide, respectively. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly MnjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDHe3Z3UUN3ME2wMlEz6oDLwsJihKkxNjBzIN88US=> NVXiXXd5OjV7NkCyPFI>
KellyCis83 Ml3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzESW1KSzVyPUCuNVbjiIoEsfMAjVAvODJizszN MYeyOVk3ODJ6Mh?=
SK-N-AS MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTBwMkVihKnDueLCiUCuNFMh|ryP MUGyOVk3ODJ6Mh?=
SK-N-ASCis24 M3Xo[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjQT2M6UUN3ME2wMlU46oDLwsJihKkxNjFzIN88US=> MY[yOVk3ODJ6Mh?=
U87 NFPpSYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXKwMVUxKM7:TR?= NYn2XWNRPDhiaB?= NHf1Wmtl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImge4hq[2hiY3HuJIJmKGWwaHHuZ4VlKGK7IIPpcIljcW6rbh?= MUmyOVc2ODJ5Mx?=
HCT116 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnYcW1QOC53LUKuOUDPxE1? NYniVFFtPDkEoHlCpC=> Mn\qTWM2OD1zLkezxsDDucLiMD6yNeKh|ryP MW[yOVc1Pjd4Mx?=
HT-29 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELBcpgxNjVvMj61JO69VQ>? M13FcFQ5yqCqwrC= NEP1NXVKSzVyPUeuNuKhyrIEoEGuNFTDqM7:TR?= NULIXFZFOjV5NE[3OlM>
Caco2 NFfsUWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rVO|AvPS1{LkWg{txO NUTVN5R{PDkEoHlCpC=> NEKwbmJKSzVyPUeuNlbDqMLzwrCxMlY5yqEQvF2= NIO4S4YzPTd2Nke2Ny=>
COLO 205 NH3nSWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVf1XHk1OC53LUKuOUDPxE1? NX2xe2FEPDkEoHlCpC=> NVLDd4Z6UUN3ME2xMlYyyqEEsdMgNE4xOsLizszN NXf3eYtuOjV5NE[3OlM>
SW480 M4LyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVKwMlUuOi53IN88US=> MojGOFjDqGkEoB?= NVXPRWxXUUN3ME20MlkzyqEEsdMgNE4{O8LizszN MXuyOVc1Pjd4Mx?=
HEK293T NEfBdVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHLNU02KM7:TR?= MnHNOFjDqGkEoB?= NUDKRmduUUN3ME2yMlQzyqEEsdMgNE4xPcLizszN MX2yOVc1Pjd4Mx?=
Hep3B  NWnxS28{TnWwY4Tpc44hSXO|YYm= MVGxNEDPxE1? M2jSVFQ5yqCqwrC= MkHYdoVlfWOnczD0bIUh\W6qYX7jbY5oKGWoZnXjeEBw\iCETWCtOi=> M1vFV|I2PjN|NU[0
Hep3B  MX3GeY5kfGmxbjDBd5NigQ>? NUP6NpNNOC5zLUGwJO69VQ>? NF;G[mwzPCCq MkXld5VxeHKnc4Pld{B1cGViZYjwdoV{e2mxbjDv[kBp\XClaXTpckBuWk6D MYGyOVY{OzV4NB?=
HEK293 M3GzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTdwMUVCpOKyyqByLkO2xsDPxE1? NWDNboljOjV4MEOxNlI>
DU145 MmPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLve3hKSzVyPUKuNljDqMLzwrCwMlA1yqEQvF2= M3q0eFI2PjB|MUKy
HCT15 NX3IWoRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHZd2tKSzVyPUCuPFHDqMLzwrCwMlAyyqEQvF2= MnLSNlU3ODNzMkK=
T47D MmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLOVo5KSzVyPUOuNVjDqMLzwrCwMlEyyqEQvF2= NFjB[mczPTZyM{GyNi=>
SMMC-7721 NU\1[mlqTnWwY4Tpc44hSXO|YYm= MYW0NEDPxE1? NEDwNm41QCCq NX[ycZY2TE2VTx?= Mn3EbY5lfWOnczFOt2gzSVhiZn;jbUBnd3KvYYTpc44> M2CxXVI2PTR2M{[x
MDA-MB-231 MoLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLOVHNlPzMEoHi= M3zKN2lEPTB;MkGuNuKhyrIEoESuNuKh|ryP NFLXNWUzPTR6NkKxPS=>
MCF-7 NI\qRVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\MXodGPzMEoHi= MUPJR|UxRTFyLkpCpOKyyqB{LkJCpO69VQ>? MYGyOVQ5PjJzOR?=
Jurkat NX6xbWV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXCO|LDqGh? M3vJZ2lEPTB;MT6yxsDDucLiMT61xsDPxE1? MX2yOVQ5PjJzOR?=
HeLa MojIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvxUY13PzMEoHi= MYDJR|UxRTNwOdMgxtHDqDJwM9Mg{txO NILqUIozPTR6NkKxPS=>
MCF7  MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjHPY1JPS1zMECg{txO NH;MdG44KGR? NHO0PFVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MlLoNlU1PzJ4MUm=
K562 NEHadmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfYSpE4OsLiaB?= MmX5TWM2OD1yLkK5xsDPxE1? NF3M[oczPTJ6Mk[1Ny=>
K/VP.5 M3zzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrSNno4OsLiaB?= MUDJR|UxRTRwOdMg{txO MVOyOVI5OjZ3Mx?=
SH-EP  M4TqdmZ2dmO2aX;uJGF{e2G7 MYGyNOKh|rypL33s NWDHXXA6OjUEoHi= MkTTbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJIVv\G:pZX7veZMhTEWSUB?= NW\qRVBDOjV{NkG5PFE>
SCC25 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjkRmEyOjUEoHi= M3fUdWlEPTB;NEOuN:KhyrIEoEGuNVLDqM7:TR?= M{\Kd|I2OjJyN{K5
CAL27 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfU[okzPMLiaB?= M1;y[mlEPTB;NUKuNeKhyrIEoEGuNFnDqM7:TR?= M33Zc|I2OjJyN{K5
FaDu MkHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnkVXkzPMLiaB?= NXXEc2FGUUN3ME2yOU45QcLiwsJCpFEvOTQEoN88US=> MnHKNlUzOjB5Mkm=
SCC25 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGi2V4I1QMLiaB?= MXLJR|UxRTJyLki2xsDDucLiMT6wO:Kh|ryP NWC4bJpKOjV{MkC3Nlk>
CAL27 NILJd3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTrOFjDqGh? MnjqTWM2OD1zOD6yOOKhyrIEoEGuNVXDqM7:TR?= NEWzOlMzPTJ{MEeyPS=>
FaDu MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LZWlQ5yqCq MoHOTWM2OD14LkSzxsDDucLiMT6xN:Kh|ryP MYiyOVIzODd{OR?=
SCC25 NXTFeYpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\IO|LDqGh? MljGTWM2OD16LkSxxsDDucLiMT6xNeKh|ryP MlLBNlUzOjB5Mkm=
CAL27 MnnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3y2T|czyqCq MV\JR|UxRTRwMkhCpOKyyqBzLkG0xsDPxE1? NY\KSZF5OjV{MkC3Nlk>
FaDu MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX63NuKhcA>? NH;yXZBKSzVyPUWuNFLDqMLzwrCxMlE2yqEQvF2= MX6yOVIzODd{OR?=
MCF-7 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYq0POKhcMLi Mn7FSG1UVw>? MljQTWM2OD15LkNCpOKyyqByLklCpO69VQ>? NXXDbI5YOjV{MU[zO|g>
T-47D NH7jdFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF:zWFg1QMLiaNMg M4fIeGROW09? M1zud2lEPTB;Nz63xsDDucLiMD63xsDPxE1? MmTKNlUzOTZ|N{i=
MDA-MB-231 M2Gw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWO0POKhcMLi NUj3TlE1TE2VTx?= M{DnbWlEPTB;MUKuPOKhyrIEoEGuNOKh|ryP NVXudJVzOjV{MU[zO|g>
DU145 MUTBdI9xfG:|aYOgRZN{[Xl? M{ThfFExNTFyMDFOwG0> MmPTPEBp MlXOSG1UVw>? M1PT[Ilv\HWlZYOgZ4VtdCCmZXH0bEB{cWewaX\pZ4FvfGy7IHnuJIEhfmW{eTDsc5ch[2:wY3XueJJifGmxbh?= MkjuNlUyPDl4OEG=
DU145 stem-like M{fZdmFxd3C2b4Ppd{BCe3OjeR?= Moq4NVAuOTByIN88US=> NHPpXJE5KGh? NH32RmFFVVOR NV32fYFWcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MX:yOVE1QTZ6MR?=
DU145 NY\kWYlHTnWwY4Tpc44hSXO|YYm= NULLS5VDOTBvMUCwJO69VQ>? NVL0Z4FsOiCq MkHISG1UVw>? MlGxbY5kemWjc3XzJJRp\SCyQ1jLNUBmgHC{ZYPzbY9vKGGwZDDk[YNz\WG|ZYOgeIhmKHCFSFuxJIV5eHKnc4Ppc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NHvWVFEzPTF2OU[4NS=>
DU145 stem-like NV7QSo1lTnWwY4Tpc44hSXO|YYm= MlTHNVAuOTByIN88US=> NVnhSXd3OiCq MkjKSG1UVw>? NWnLSIJScW6lcnXhd4V{KHSqZTDwR2hMOSCneIDy[ZN{cW:wIHHu[EBl\WO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NUTPV2dvOjVzNEm2PFE>
UW228-3 M{nyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\YPXcxNjBzLUOwNEDPxE1? M{n0c|Q5KGh? M3T5cmROW09? NUXVb2lIUUN3ME2wMlk6yqEQvF2= Moi4NlUyOTlzOEW=
NSCs MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4W5b|AvODFvM{CwJO69VQ>? MWm0PEBp M4KzV2ROW09? MmDGTWM2OD1yLkOtN:Kh|ryP MWOyOVEyQTF6NR?=
MKL-1  M1:4R2Z2dmO2aX;uJGF{e2G7 NUHPUZFwOTBvMUCwNEBvVQ>? NWr5THkzPCCm MlfZbY5lfWOnczD0bIUhcW6mdXP0bY9vKG:oIF3IR{1KKGW6cILld5Nqd25? NYLEUmpWOjVzMU[3OVQ>
MCF7 EV NIPqRpVHfW6ldHnvckBCe3OjeR?= NGnn[YMyOC1zMECg{txO M3TYTVLjiImq M2\nWIlv\HWlZYOgdJJw\HWldHnvckBw\sLizsPINmFZ M{jCN|I2ODh6MkCz
MCF 7BMI1 MYrGeY5kfGmxbjDBd5NigQ>? NVnTSmhlOTBvMUCwJO69VQ>? NWe4WIN6OuLCiXi= MVjpcoR2[2W|IIDyc4R2[3Srb36gc4bDqM7|SELBXC=> MVSyOVA5QDJyMx?=
MCF7 EV MYfGeY5kfGmxbjDBd5NigQ>? MWmxNE0yODBizszN NFWwNFUz6oDLaB?= MXjFWG9RKGmwZIXj[ZMhSVSPIHHjeIl3[XSrb36= MnLLNlUxQDh{MEO=
MCF7 BMI1 M4f2XWZ2dmO2aX;uJGF{e2G7 NIHUZnEyOC1zMECg{txO NWrUUZk1OuLCiXi= NV:1W5Q1TVSRUDDpcoR2[2W|IFHUUUBi[3SrdnH0bY9v MmLONlUxQDh{MEO=
HepG2 MnzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmS0SG1UV8Li NWX2empXUUN3ME2zNE4yPsLiwsJCpFAvPTEEoN88US=> NWDiNIxyOjVyN{izNVE>
MOLT-3 NF;5XWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfhWlBRTE2VT9Mg MV\JR|UxRTBwMEWxxsDDucLiMD6wNFLDqM7:TR?= MmnnNlUxPzh|MUG=
HT1080 NXzWXo5UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDEXJMyNTFyMDFOwG0> NVnOTZpTPC9{ND:0PEBp NFWzcVBFVVORwrC= Mn7DbY5lfWOnczDj[YxtKGSnYYToJJNq\26rZnnjZY51dHliaX6gZUB3\XK7IHzve{Bkd26lZX70doF1cW:w M3LrSlI2ODd6ME[0
HT1080 M{P2b2Z2dmO2aX;uJGF{e2G7 NIL3S5kxNjByMEGtNVAxKM7:TR?= NIK0cYcyNTJ2IHi= NHTpPGVFVVORwrC= Ml7lbY5lfWOnczDwMZA2Oyi|ZYKxOUkhcW5iYn;0bEB1cW2nLTDhcoQh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{ M4HUNVI2ODd6ME[0
HT1080 NVjDVIRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrHWphVOC5yMECxMVExOCEQvF2= NEnkb3czPCCq NXPyfHZRTE2VT9Mg Mmj3Z4F2e2W|IHHuJIlv[3KnYYPlJIlvKHSqZTDueY1j\XJib3[gZ4VtdHNiaX6gS|IwVSxid3jpcIUh\GWlcnXhd4lv\yCVIHHu[EBIOSCyaHHz[UBk\Wyucx?= MlXBNlUxPzhyNkS=
HD-MY-Z M174XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXKyOE81QC95MjDo NUjwR3VDUUN3MP-8olExOCEQvF2= MXiyOVA1QDJ|Nh?=
DOHH-2 MonMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfu[FUzPCCq NW\4OGZwUUN3MP-8olExOCEQvF2= MoPGNlUxPDh{M{[=
DOHH-2 MmfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDafY57PDhiaB?= M{P2XWlEPTB;MUmuPeKh|ryP NULpeoFVOjVyNEiyN|Y>
DOHH-2 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{f1ZlczKGh? NIrGcoNKSzVyPUZCpO69VQ>? MUiyOVA1QDJ|Nh?=
REH M{jFUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1foR|I1KGh? NHvPPVdKSzVyPUCuNFI4yqEQvF2= MkG1NlUxPDh{M{[=
REH NHTWcGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUS0PEBp MV\JR|UxRTBwMEG0xsDPxE1? MUSyOVA1QDJ|Nh?=
REH MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHE[5U4PzJiaB?= NGTSVXBKSzVyPUCuNFE2yqEQvF2= NFXMe4kzPTB2OEKzOi=>
HH NVHuWnU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPQZ5l[OjRiaB?= MlXQTWM2OD1zMESuO:Kh|ryP M{DFT|I2ODR6MkO2
HH NHXZeJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jtUlQ5KGh? M{j0XWlEPTB;NEiuOuKh|ryP M1TEVFI2ODR6MkO2
HH NEXZ[5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUW3NkBp NVfFc|M2UUN3ME2xOE44yqEQvF2= M1jtfVI2ODR6MkO2
HuT-78 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFy4SIozPCCq NV3EVnNtUUN3ME25MlPDqM7:TR?= MlfXNlUxPDh{M{[=
HuT-78 MkLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVe0PEBp NGLxZXdKSzVyPUSuN:Kh|ryP M3flV|I2ODR6MkO2
HuT-78 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojGO|IhcA>? M1PI[WlEPTB;ND6yxsDPxE1? MYGyOVA1QDJ|Nh?=
OPM-2 NFe3[odIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE[zZZczPCCq Ml:1TWM2OD1{ND6xxsDPxE1? NHnCSJYzPTB2OEKzOi=>
OPM-2 MoTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\6eFB5PDhiaB?= MmTvTWM2OD12wrFOwG0> MmLhNlUxPDh{M{[=
OPM-2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWr3V4hMPzJiaB?= NHTMR3JKSzVyPUGuN:Kh|ryP NFW0OG4zPTB2OEKzOi=>
RPMI-8226 M2jmeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fLRlI1KGh? MUTJR|UxRTFyNj62xsDPxE1? MnnCNlUxPDh{M{[=
RPMI-8226 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrWOFghcA>? MXrJR|UxRTlzLkJCpO69VQ>? NVjWbIdpOjVyNEiyN|Y>
RPMI-8226 NF3sXI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXq3NkBp M1SwWWlEPTB;MUSuPeKh|ryP NYTxeI1SOjVyNEiyN|Y>
U-266 MnP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{T6[VI1KGh? M2TlO2lEPTB;OE[uNuKh|ryP NHviZokzPTB2OEKzOi=>
U-266 Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LLVlQ5KGh? MWfJR|UxRTZ6LkVCpO69VQ>? M1vwflI2ODR6MkO2
U-266 NHPudWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jDSVczKGh? NIm5SnVKSzVyPUK3MlTDqM7:TR?= NU\oSnd3OjVyNEiyN|Y>
Kelly MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY[wMVExKM7:TR?= MVS3NuKhcA>? M{TDNmlEPTB;MT61NVjDqM7:TR?= NWL2[ZZXOjVyMEi5NFA>
SH-SY5Y  M1[zdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLpNE0yOCEQvF2= NI\1fmk4OsLiaB?= NGXLdHBKSzVyPUCuO|U1yqEQvF5CpC=> NIH2e3kzPTByOEmwNC=>
SK-N-AS NXn5ZmFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDyNE0yOCEQvF2= MlT6O|LDqGh? MX\JR|UxRTFwN{GyxsDPxE4EoB?= MoLQNlUxODh7MEC=
SK-N-DZ MoL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvLT2pGOC1zMDFOwG0> Ml7uO|LDqGh? NUDZVJVyUUN3ME21MlQ5PcLizszN MXyyOVAxQDlyMB?=
HepG2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVi2VGZwPDkEoHi= M{\5dWROW00EoB?= MoPETWM2OD1zMz62OeKhyrIEoECuPVLDqM7:TR?= MljjNlQ6QTZzM{[=
A549 M1TTO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\vOFjDqGh? NV[0TI9LTE2VT9Mg MkHETWM2OD1{NEGuPeKhyrIEoEOxMlI{yqEQvF2= NUXJS4JOOjR7OU[xN|Y>
MCF7 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3jOFjDqGh? M4fxcWROW00EoB?= MnO1TWM2OD16MT6wPeKhyrIEoEG0MlIyyqEQvF2= MXuyOFk6PjF|Nh?=
HL-60  MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGT5Rm84OsLiaB?= NY\UZnlPUUN3ME2wMlEz6oDHzszN MlPQNlQ6QTNyMUS=
HL-60[R] MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;GOlczyqCq MWDJR|UxRTNwMUNihKXPxE1? MoHqNlQ6QTNyMUS=
MIAPACA M3z6eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXzSmx3T0l3ME2xMlMhyrFiMD6wN{DPxE1? MkTkNlQ6PTN6MkG=
MCF-7 NYKyVlJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYT3UYxsT0l3ME2wMlI2KMLzIECuNUDPxE1? MXmyOFk2Ozh{MR?=
HeLa NEjpdHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnpe5FIUTVyPUCuOlQhyrFiMD60JO69VQ>? M1PnTlI1QTV|OEKx
MO59K  NYq0RlRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLDO{Bl MlzoTWM2OD1yLkG35qCG|ryP NIC2[VIzPDl3M{W2NS=>
MO59J MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3mwS|ch\A>? M1LWTWlEPTB;MD6x5qCG|ryP NWHMOJkyOjR7NUO1OlE>
ME 180 NEDpR2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXK0POKhcMLi M{TkbWlEPTB;OD65xsDDucLiMD6z5qCG|ryP NHiwVXozPDl3M{CyOy=>
MCF-7 Mo\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzM[2Q1QMLiaNMg M2[xWGlEPTB;MkOuPUDDuSByLkRihKXPxE1? MoDHNlQ6PTNyMke=
HeLa MkezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW[0POKhcMLi NWnIU2tzUUN3ME20MlcyKMLzIEGuOQKBjc7:TR?= NFX1b2wzPDl3M{CyOy=>
MDA-MB-453 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX20POKhcMLi MYnJR|UxRTF{LkWgxtEhOC56NfMAie69VQ>? M3vtXFI1QTV|MEK3
MDA-MB-231 NEHzdHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\rPYRIPDkEoHlCpC=> NEnCeVJKSzVyPUK0MlIzKMLzIEKuPVTjiIYQvF2= MW[yOFk2OzB{Nx?=
PC-3 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vqSVQ5yqCqwrC= MlLuTWM2OD1zND60JOKyKDNwMkRihKXPxE1? MXOyOFk2OzB{Nx?=
HT-29 NV3NcnE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nDNFQ5yqCqwrC= NWTLUWhpUUN3ME2yNU41PSEEsTCzMlg46oDHzszN MX[yOFk2OzB{Nx?=
BGC-823 MlO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfRV3ZFPDkEoHlCpC=> MVLJR|UxRTR|Lke0JOKyKDVwMURihKXPxE1? NYDxbZpGOjR5OUO4O|c>
HeLa M4\pVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXSV25rPDkEoHlCpC=> NYrRVlRGUUN3ME2yNFkvQTBiwsGgNVMvPDJi4pEF{txO MkTPNlQ4QTN6N{e=
A549 MmjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYm0POKhcMLi M4HvT2lEPTB;MUO5MlU1KMLzIEeuNFXjiIYQvF2= M2LLVlI1Pzl|OEe3
HK-2 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7wcZI1QMLiaNMg MoflTWM2OD17LkG3JOKyKDFwNUlihKXPxE1? MWmyOFc6Ozh5Nx?=

... Click to View More Cell Line Experimental Data

In vivo Etoposide administrated as a single agent is found to been ineffective in many xenografts growth, such as Heterotransplanted Hepatoblastoma NMHB1, and NMHB 2, [6] human neuroblastoma xenograft, [7] and human gastrointestinal cancer xenograft, [8] while the dose of 10 mg/kg i.p. Etoposide inhibits murine angiosarcoma cell ISOS-1 tumors in 36% of controls. [2] Etoposide induces tumor immunity in Lewis lung cancer. A single administration of 50 mg/kg Etoposide i.p., induces a 60% survival of C57B1/6 mice injected with Lewis lung cancer cell (3LL) over 60 days. About 40% of these surviving mice reject a subsequent challenge with 3LL, while none of control mice survive beyond 30 days. 3LL cells which have survived an 90% lethal concentration of Etoposide in vitro kill 75% of recipient mice, but 60% surviving mice reject challenge with 3LL. Splenocytes harvested from tumor rejecting mice protect naive mice injected with 3LL. [9]

Protocol

Kinase Assay:[5]
+ Expand

Topoisomerase II activity assay:

Nuclear extracts are prepared, and nuclei are isolated. The activity of topoisomerase II is calculated from the percentage of decatenation obtained. Tritiated kinoplast DNA (KDNA 0.22 μg) is used as a substrate. Etoposide and topoisomerase II are incubated for 30 min at 37 ℃ and are stopped with 1% sodium dodecyl sulfate (SDS) and proteinase K (100 μg/mL). The percentages of decatenation and inhibition of topoisomerase II by Etoposide are obtained.
Cell Research:[5]
+ Expand
  • Cell lines: Human glioma cell lines CL5
  • Concentrations: 80 μg/mL
  • Incubation Time: 1 hour
  • Method: After the Etoposide treatment, cells are removed from the dish with phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA) and are diluted into culture dishes in appropriate numbers to yield between 20 and 200 colonies. After 12 days, cultures are fixed with methanol-acetic acid, stained with crystal violet, and scored for colonies containing more than 50 cells. The standard errors are typically less than 15% of the mean value unless otherwise stated.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Murine angiosarcoma xenografts ISOS-1
  • Formulation: Saline
  • Dosages: 10 mg/kg
  • Administration: i.p. every day for 5 days from day 7
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+H2O
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 588.56
Formula

C29H32O13

CAS No. 33419-42-0
Storage powder
in solvent
Synonyms VP-16, VP-16213

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03036904 Not yet recruiting Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma Weill Medical College of Cornell University|Genentech, Inc.|Massachusetts General Hospital|M.D. Anderson Cancer Center February 6, 2017 Phase 1
NCT02432274 Recruiting Tumors|Solid Malignant Tumors|Osteosarcoma|Differentiated Thyroid Cancer (DTC) Eisai Limited|Eisai Inc. December 29, 2014 Phase 1|Phase 2
NCT02385110 Recruiting Leukemia M.D. Anderson Cancer Center September 23, 2015 Phase 2
NCT03007147 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Childrens Oncology Group|National Cancer Institute (NCI) July 2017 Phase 3
NCT03016871 Not yet recruiting CD (Cluster of Differentiation) 30-Positive Neoplastic Cells Present|Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma City of Hope Medical Center|National Cancer Institute (NCI) June 2017 Phase 2
NCT03041311 Not yet recruiting Small Cell Lung Cancer G1 Therapeutics, Inc. May 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • Answer:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products

Tags: buy Etoposide | Etoposide supplier | purchase Etoposide | Etoposide cost | Etoposide manufacturer | order Etoposide | Etoposide distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID